TheNote.app
STAT | Reporting from the frontiers of health and medicine

STAT+: GSK pays $500M upfront for rights to series of Hengrui drugs

GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese firm to build out its pipeline.
favicon
statnews.com
statnews.com
Image for the article: STAT+: GSK pays $500M upfront for rights to series of Hengrui drugs
RSS Hunter
© 2015-2025, TheNote.app
· Privacy Policy · Terms & Conditions · Contact · Android iOS MacOS